European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy.
- Published in:
- BMC Endocrine Disorders, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1472-6823-14-40
- By:
- Publication type:
- Article
Works matching AU Fitts, David
Results: 11
1
2
Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials.
- Published in:
- Clinical Infectious Diseases, 2014, v. 59, n. 3, p. 345
- By:
- Publication type:
- Article
3
Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.
- Published in:
- Open Forum Infectious Diseases, 2020, v. 7, n. 6, p. 1, doi. 10.1093/ofid/ofaa209
- By:
- Publication type:
- Article
4
Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.
- Published in:
- Open Forum Infectious Diseases, 2020, v. 7, n. 5, p. 1, doi. 10.1093/ofid/ofaa145
- By:
- Publication type:
- Article
5
676. Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2)
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S308, doi. 10.1093/ofid/ofz360.744
- By:
- Publication type:
- Article
6
2245. Oral 5-Day Lefamulin for Outpatient Management of Pneumonia Outcomes Research Team (PORT) Risk Class III/IV Community-Acquired Bacterial Pneumonia (CABP): Post Hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 Study.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S767, doi. 10.1093/ofid/ofz360.1923
- By:
- Publication type:
- Article
7
Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema.
- Published in:
- American Journal of Rhinology & Allergy, 2013, v. 27, n. 6, p. 517, doi. 10.2500/ajra.2013.27.3973
- By:
- Publication type:
- Article
8
A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
- Published in:
- Cancer (0008543X), 1996, v. 78, n. 1, p. 144, doi. 10.1002/(SICI)1097-0142(19960701)78:1<144::AID-CNCR20>3.0.CO;2-Z
- By:
- Publication type:
- Article
9
Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks.
- Published in:
- Allergy & Asthma Proceedings, 2014, v. 35, n. 5, p. 371, doi. 10.2500/aap.2014.35.3783
- By:
- Publication type:
- Article
10
Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women.
- Published in:
- Allergy & Asthma Proceedings, 2013, v. 34, n. 2, p. 162, doi. 10.2500/aap.2013.34.3645
- By:
- Publication type:
- Article
11
Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks.
- Published in:
- Allergy & Asthma Proceedings, 2012, v. 33, n. 4, p. 348, doi. 10.2500/aap.2012.33.3585
- By:
- Publication type:
- Article